Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
First Claim
Patent Images
1. A method of treating a patient in need thereof, comprising administering an effective amount of a modified FGF-21 polypeptide to said patient, wherein said modified FGF-21 polypeptide maintains the biological activity of human FGF-21 polypeptides and comprises a non-naturally encoded amino acid, wherein:
- (a) the polypeptide comprises a sequence at least 90% identical to SEQ ID NO;
1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, or SEQ ID NO;
7;
(b) the non-naturally encoded amino acid has the structure;
1 Assignment
0 Petitions
Accused Products
Abstract
Modified FGF-21 polypeptides and uses thereof are provided.
-
Citations
20 Claims
-
1. A method of treating a patient in need thereof, comprising administering an effective amount of a modified FGF-21 polypeptide to said patient, wherein said modified FGF-21 polypeptide maintains the biological activity of human FGF-21 polypeptides and comprises a non-naturally encoded amino acid, wherein:
-
(a) the polypeptide comprises a sequence at least 90% identical to SEQ ID NO;
1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, or SEQ ID NO;
7;(b) the non-naturally encoded amino acid has the structure; - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method of treating a patient in need thereof, comprising administering an effective amount of a modified FGF-21 polypeptide to said patient, wherein said modified FGF-21 polypeptide maintains the biological activity of human FGF-21 polypeptides and comprises the polypeptide of SEQ ID NO:
- 1 except that an amino acid in the polypeptide is substituted by a non-naturally encoded amino acid, wherein;
(a) said non-naturally encoded amino acid is at a position corresponding to residue 108 of SEQ ID NO;
1;(b) said non-naturally encoded amino acid comprises para-acetyl phenylalanine linked to a polymer comprising a poly(ethylene glycol), wherein said poly(ethylene glycol) has an average molecular weight of about 30 kDa; and (c) said non-naturally encoded amino acid is linked to said polymer through an oxime linkage. - View Dependent Claims (7)
- 1 except that an amino acid in the polypeptide is substituted by a non-naturally encoded amino acid, wherein;
-
8. A method of treating a patient in need thereof, comprising administering an effective amount of a modified FGF-21 polypeptide to said patient, wherein said modified FGF-21 polypeptide maintains the biological activity of human FGF-21 polypeptides and comprises a non-naturally encoded amino acid, wherein:
-
(a) the polypeptide comprises a sequence at least 95% identical to SEQ ID NO;
1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, SEQ ID NO;
6, or SEQ ID NO;
7;(b) the non-naturally encoded amino acid has the structure; - View Dependent Claims (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification